ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)
The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. This editorial reflects on key breakthroughs presented at GU ASCO 2026 and their implications for clinical practice.
This narrative review summarizes the current evidence for molecular and genomic biomarkers in small renal mass risk stratification and evaluates their potential role in guiding clinical management decisions.
Recent research has identified PIWI-interacting RNAs and PIWI-like proteins as potential biomarkers and therapeutic targets in RCC. This review evaluates their translational readiness for clinical practice.
Renal cell carcinoma accounts for 4.2% of adult malignancies and is the 10th leading cause of cancer deaths in the United States. This study evaluates urinary biomarkers for non-invasive tumour grading.
This quarter’s selection highlights landmark studies in first-line combination immunotherapy and biomarker-driven patient selection for adjuvant therapy in localized RCC.
A comprehensive summary of pivotal kidney cancer presentations from the 2026 ASCO Genitourinary Cancers Symposium, including phase 3 readouts and practice-changing biomarker data.
Curated abstracts and poster presentations from GU ASCO 2026 covering immunotherapy combinations, targeted agents, and emerging biomarker strategies in renal cell carcinoma.
Replace this text with the first 1–2 sentences of the abstract or a brief summary of the case report.